

Cecilia G Carvalhaes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3704775/publications.pdf>

Version: 2024-02-01

57
papers

1,331
citations

394421

19
h-index

377865

34
g-index

58
all docs

58
docs citations

58
times ranked

1669
citing authors

#	ARTICLE	IF	CITATIONS
1	Multidrug-resistant <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> : resistance mechanisms and implications for therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 71-93.	4.4	256
2	Cloverleaf test (modified Hodge test) for detecting carbapenemase production in <i>Klebsiella pneumoniae</i> : be aware of false positive results. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 249-251.	3.0	178
3	Detection of carbapenemase activity directly from blood culture vials using MALDI-TOF MS: a quick answer for the right decision. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2132-2136.	3.0	62
4	Detection of SPM-1-Producing <i>Pseudomonas aeruginosa</i> and Class D β -Lactamase-Producing <i>Acinetobacter baumannii</i> Isolates by Use of Liquid Chromatography-Mass Spectrometry and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2013, 51, 287-290.	3.9	56
5	Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	42
6	OXA-72-producing <i>Acinetobacter baumannii</i> in Brazil: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 452-454.	3.0	40
7	Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 93-102.	1.8	39
8	Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
9	Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant <i>Serratia marcescens</i> Isolates from an Outbreak in a Brazilian Teaching Hospital. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2324-2328.	3.9	32
10	Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114833.	1.8	32
11	Risk factors for KPC-producing <i>Klebsiella pneumoniae</i> : watch out for surgery. <i>Journal of Medical Microbiology</i> , 2016, 65, 547-553.	1.8	31
12	Outbreak of Carbapenem-Resistant <i>Providencia stuartii</i> in an Intensive Care Unit. <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 627-630.	1.8	28
13	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012-2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115016.	1.8	26
14	Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. <i>International Journal of Infectious Diseases</i> , 2020, 91, 32-37.	3.3	24
15	Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
16	<i>In Vitro</i> Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
17	Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America. <i>International Journal of Infectious Diseases</i> , 2018, 77, 82-86.	3.3	22
18	Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2907-2913.	3.0	22

#	ARTICLE	IF	CITATIONS
19	Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016). <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
20	Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014â€“19). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2600-2605.	3.0	21
21	Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018â€“2020). <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115557.	1.8	21
22	Identification of a New Integron Harboring <i>bla</i> _{IMP-10} in Carbapenem-Resistant <i>Acinetobacter baumannii</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3687-3689.	3.2	20
23	Old Clinical Isolates of <i>Acinetobacter seifertii</i> in Brazil Producing OXA-58. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2589-2591.	3.2	20
24	Dissemination of Multidrug-Resistant <i>Proteus mirabilis</i> Clones Carrying a Novel Integron-Borne <i>bla</i> _{IMP-1} in a Tertiary Hospital. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	14
25	Influence of Culture Media on Detection of Carbapenem Hydrolysis by Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2016, 54, 1896-1898.	3.9	13
26	Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. <i>Medical Mycology</i> , 2022, 60, .	0.7	13
27	Evaluation of a rapid immunochromatographic test for detection of distinct variants of <i>Klebsiella pneumoniae</i> carbapenemase (KPC) in Enterobacteriaceae. <i>Journal of Microbiological Methods</i> , 2017, 142, 1-3.	1.6	12
28	Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014â€“17). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1928-1933.	3.0	12
29	Assessment of Tedizolid <i>In Vitro</i> Activity and Resistance Mechanisms against a Collection of <i>Enterococcus</i> spp. Causing Invasive Infections, Including Isolates Requiring an Optimized Dosing Strategy for Daptomycin from U.S. and European Medical Centers, 2016 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	12
30	Comparative activity of newer β -lactam/ β -lactamase inhibitor combinations against <i>Pseudomonas aeruginosa</i> from patients hospitalized with pneumonia in European medical centers in 2020. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 319-324.	2.9	12
31	Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019â€“2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 477-487.	2.9	12
32	Detection of carbapenemase activity using VITEK MS: interplay of carbapenemase type and period of incubation. <i>Journal of Medical Microbiology</i> , 2015, 64, 946-947.	1.8	11
33	<i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>Klebsiella pneumoniae</i> in the Intensive Care Unit. <i>Shock</i> , 2013, 39, 32-37.	2.1	10
34	Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 17, 103-108.	2.2	10
35	Tedizolid activity against a multicentre worldwide collection of <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> recovered from patients with pneumonia (2017â€“2019). <i>International Journal of Infectious Diseases</i> , 2021, 107, 92-100.	3.3	9
36	In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115473.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020). <i>Journal of Clinical Microbiology</i> , 2022, 60, e0244921.	3.9	9
38	Co-transmission of <i>Rahnella aquatilis</i> between hospitalized patients. <i>Brazilian Journal of Infectious Diseases</i> , 2015, 19, 648-650.	0.6	8
39	Detection of OXA-370 directly from rectal swabs and blood culture vials using an immunochromatographic assay. <i>Journal of Microbiological Methods</i> , 2017, 139, 92-94.	1.6	8
40	Nocardial scleritis: A case report and a suggested algorithm for disease management based on a literature review. <i>American Journal of Ophthalmology Case Reports</i> , 2018, 10, 1-5.	0.7	7
41	Direct matrix-assisted laser desorption ionization time-of-flight mass spectrometry and real-time PCR in a combined protocol for diagnosis of bloodstream infections: a turnaround time approach. <i>Brazilian Journal of Infectious Diseases</i> , 2019, 23, 164-172.	0.6	7
42	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016-19). <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab117.	2.1	7
43	Avaliação das metodologias M.I.C.E.®, Etest® e microdiluição em caldo para determinação da CIM em isolados clínicos. <i>Jornal Brasileiro De Patologia E Medicina Laboratorial</i> , 2011, 47, 157-164.	0.3	6
44	High mortality rate associated with KPC-producing <i>Enterobacter cloacae</i> in a Brazilian hospital. <i>American Journal of Infection Control</i> , 2018, 46, 108-110.	2.3	6
45	Rapid detection of ceftazidime/avibactam resistance by MALDI-TOF MS. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2579-2582.	3.0	6
46	Ceftaroline activity against <i>Staphylococcus aureus</i> isolated from patients with infective endocarditis, worldwide (2010-2019). <i>International Journal of Infectious Diseases</i> , 2021, 102, 524-528.	3.3	6
47	Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0166721.	3.2	6
48	Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab088.	2.1	5
49	Comparison of M.I.C.E. and Etest with CLSI Agar Dilution for Antimicrobial Susceptibility Testing against Oxacillin-Resistant <i>Staphylococcus</i> spp. <i>PLoS ONE</i> , 2014, 9, e94627.	2.5	5
50	Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018-2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 867-873.	2.9	5
51	Molecular Diagnosis Contributing for Multi-Drug Resistant Infection Control. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 17-39.	1.9	4
52	Activity of Tedizolid and Comparator Agents Against Gram-positive Isolates Causing Skin and Skin Structure Infections in Pediatric Patients in United States Hospitals (2015-2019). <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 731-735.	2.0	3
53	Evaluation of the Post-antifungal Effect of Rezafungin and Micafungin against <i>Candida albicans</i> , <i>Candida parapsilosis</i> and <i>Candida glabrata</i> . <i>Mycoses</i> , 0, , .	4.0	3
54	Comment on: Performance of the Oxoid M.I.C.Evaluator™ Strips compared with the Etest(R) assay and BSAC agar dilution. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1192-1193.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Rapid detection of bla KPC directly from surveillance rectal swabs by EasyQ KPC. Diagnostic Microbiology and Infectious Disease, 2018, 90, 251-252.	1.8	2
56	2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. Open Forum Infectious Diseases, 2019, 6, S716-S716.	0.9	1
57	Plain language summary: Does a person's age affect how common fungal infections are and how well drugs can kill the infections?. Future Microbiology, 2022, , .	2.0	0